• Order to parcel locker

    Order to parcel locker
  • easy pay

    easy pay
  • Reduced price
  • New
Elsevier's 2025 Intravenous Medications

Elsevier's 2025 Intravenous Medications

A Handbook for Nurses and Health Professionals

9780443120404
262.03 zł
222.73 zł Save 39.30 zł Tax included
Lowest price within 30 days before promotion: 222.73 zł
Quantity
Teaser

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description
**Selected for Doody’s Core Titles® 2024 with Essential Purchase designation in Pharmacology**

Find the essential information you need to safely administer more than 400 intravenous drugs! For nearly 50 years, Elsevier’s Intravenous Medications:: A Handbook for Nurses and Health Professionals has been a trusted resource for complete, accurate drug information in a concise, quick-access format. New to the 2025 edition are 16 monographs of the most recent IV drugs to be approved by the FDA, in addition to updated drug uses, interactions, precautions, alerts, and patient teaching instructions for all current IV drugs. Known as the #1 IV drug handbook on the market, this annual publication is ideal for use in critical care areas, at the nursing station, in the office, and in public health and home care settings.
Product Details
Elsevier
99704
9780443120404
9780443120404

Data sheet

Publication date
2024
Issue number
41
Cover
soft binded
Pages count
1344
Dimensions (mm)
152 x 229
Weight (g)
450
  • Evolve website information
    General Dilution Charts
    How to Use This Book
    Preface
    Format and Content of Intravenous Medications
    Key to Abbreviations
    Important IV Therapy Facts
    Resources
    Preparation and Administration of Injectable Drugs
    IV Drugs
    Appendix A: Recommendations for the Safe Use and Handling of Cytotoxic Drugs
    Appendix B: FDA Pregnancy Categories
    Appendix C: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE)
    Appendix D: Information for Patients Receiving Immunosuppressive Agents
    Appendix E: Recently Approved Drugs
    Index
Comments (0)